{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:10:51Z","timestamp":1789506651725,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005639","name":"Universidade de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["302977\/2021-0"],"award-info":[{"award-number":["302977\/2021-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128836","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:37:14Z","timestamp":1781278634000},"page":"128836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Autologous tumor-based vaccines in canine oncology: a systematic review of safety, immunogenicity, and therapeutic potential"],"prefix":"10.1016","volume":"88","author":[{"given":"Juliana Rodrigues","family":"Leit\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Roberto Vidal","family":"Tuani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Sim\u00f5es Tiagua","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia Maria","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"de Oliveira Massoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"Fonseca-Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2026.128836_bb0005","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.18632\/oncotarget.12739","article-title":"The concept of immune surveillance against tumors: the first theories","volume":"8","author":"Ribatti","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128836_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267648","article-title":"Factors related to the suppression of the antitumour immune response in female dogs with inflammatory mammary carcinoma","volume":"17","author":"Damasceno","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128836_bb0015","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1098612X211031504","article-title":"Field safety experience with an autologous cancer vaccine in tumor-bearing cats: a retrospective study of 117 cases (2015\u20132020)","volume":"24","author":"Lucroy","year":"2022","journal-title":"J Feline Med Surg"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128836_bb0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1476-5829.2007.00128.x","article-title":"Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumor cell vaccination in the treatment of canine B-cell multicentric lymphoma","volume":"5","author":"Turek","year":"2007","journal-title":"Vet Comp Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128836_bb0025","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-13-2283","article-title":"Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma","volume":"20","author":"Marconato","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128836_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cancers11020137","article-title":"Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma","volume":"11","author":"Olin","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128836_bb0035","doi-asserted-by":"crossref","DOI":"10.4142\/jvs.2019.20.e48","article-title":"Autologous hybrid cell fusion vaccine in a spontaneous intermediate model of breast carcinoma","volume":"20","author":"Bird","year":"2019","journal-title":"J Vet Sci"},{"key":"10.1016\/j.vaccine.2026.128836_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2024.106196","article-title":"Prospective study of successful autologous dendritic cell therapy in dogs with splenic stage II hemangiosarcoma","volume":"306","author":"Spiller","year":"2024","journal-title":"Vet J"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128836_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024167","article-title":"CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin\u2019s lymphoma","volume":"6","author":"Sorenmo","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128836_bb0050","article-title":"Association of Systemic Inflammatory and Immune Indices With Survival in Canine Patients With Oral Melanoma, Treated With Experimental Immunotherapy Alone or Experimental Immunotherapy Plus Metronomic Chemotherapy","volume":"6","author":"Garcia","year":"2022","journal-title":"Front Vet Sci"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128836_bb0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/2326-6066.CIR-13-0157","article-title":"Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines","volume":"2","author":"Weir","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.vaccine.2026.128836_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.vetimm.2016.10.011","article-title":"Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs","volume":"182","author":"Yannelli","year":"2016","journal-title":"Vet Immunol Immunopathol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128836_bb0065","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.21873\/anticanres.13275","article-title":"Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model","volume":"39","author":"Crossley","year":"2019","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128836_bb0070","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/0008-5472.CAN-12-3366","article-title":"Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity","volume":"73","author":"Andersen","year":"2013","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128836_bb0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/vetsci5040087","article-title":"The Safety of an Adjuvanted Autologous Cancer Vaccine Platform in Canine Cancer Patients","volume":"5","author":"Weir","year":"2018","journal-title":"Vet Sci"},{"issue":"39","key":"10.1016\/j.vaccine.2026.128836_bb0080","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1016\/j.vaccine.2015.08.017","article-title":"Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma","volume":"33","author":"Marconato","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128836_bb0085","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s40425-019-0624-y","article-title":"Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers","volume":"7","author":"Marconato","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128836_bb0090","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tvjl.2015.07.009","article-title":"Peripheral blood lymphocyte\/monocyte ratio as a useful prognostic factor in dogs with diffuse large B-cell lymphoma receiving chemoimmunotherapy","volume":"206","author":"Marconato","year":"2015","journal-title":"Vet J"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128836_bb0095","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jvim.15852","article-title":"Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma","volume":"34","author":"Flesner","year":"2020","journal-title":"J Vet Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128836_bb0100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12917-020-02675-y","article-title":"Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study","volume":"16","author":"Lucroy","year":"2020","journal-title":"BMC Vet Res"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128836_bb0105","article-title":"Pilot Acute Safety Evaluation of Innocell\u2122 Cancer Immunotherapy in Canine Subjects","volume":"2020","author":"Goodrich","year":"2020","journal-title":"J Immunol Res"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128836_bb0110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/BF00205649","article-title":"Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Further experimental studies on chessboard vaccination in canine mammary tumors","volume":"23","author":"Sedlacek","year":"1986","journal-title":"Cancer Immunol Immunother"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128836_bb0115","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1089\/hum.1998.9.13-1851","article-title":"Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer","volume":"9","author":"Hogge","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128836_bb0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1476-5829.2010.00234.x","article-title":"Immunotherapy with autologous tumor antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma","volume":"9","author":"Henson","year":"2011","journal-title":"Vet Comp Oncol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128836_bb0125","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/08923973.2018.1523928","article-title":"Autologous canine immunotherapy: short-time generated dendritic cells loaded with canine transmissible venereal tumor-whole lysate","volume":"40","author":"Franco-Molina","year":"2018","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2026.128836_bb0130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41417-019-0080-3","article-title":"Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma","volume":"26","author":"Konduri","year":"2019","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128836_bb0135","article-title":"Immunotherapeutic allogeneic dendritic cell and autologous tumor cell fusion vaccine alone or combined with radiotherapy in canine oral malignant melanoma is safe and potentially effective","volume":"20","author":"Xia","year":"2024","journal-title":"Front Vet Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128836_bb0140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/vco.12677","article-title":"Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"LeBlanc","year":"2021","journal-title":"Vet Comp Oncol"},{"key":"10.1016\/j.vaccine.2026.128836_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s44356-025-00051-2","article-title":"Transcriptomic profiling reveals prognostic gene signatures and immune landscape alterations in canine diffuse large B-cell lymphoma","volume":"3","author":"Ana\u00ed","year":"2026","journal-title":"Vet Oncol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26006456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26006456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:34:51Z","timestamp":1789504491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26006456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"alternative-id":["S0264410X26006456"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128836","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous tumor-based vaccines in canine oncology: a systematic review of safety, immunogenicity, and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128836"}}